Jupiter Neurosciences, Inc., formerly Jupiter Orphan Therapeutics, Inc., is a clinical stage research and development pharmaceutical company. The Company develops a resveratrol platform product targeting treatment of neuro-inflammation. The Company's product candidate, JOTROL, which primarily targets mucopolysaccharidoses Type 1, Friedreich’s Ataxia, and MELAS as well as amyotrophic lateral sclerosis (ALS) which is in an early development stage. The JOTROL delivery platform allows resveratrol to be consumed in a soft gel capsule form. It offers therapeutic benefit to central nervous system diseases such as Alzheimer’s disease, ataxias, and metabolic disorders such as Lysosomal Storage Disorders and mitochondrial diseases. It targets Mild Cognitive Impairment/early Alzheimer’s disease with traumatic brain injury (TBI)/concussions and Covid-19 in early development stages. The Company's product candidate, JOTROL, is in Phase I clinical trial.